Skip to Content
MilliporeSigma
All Photos(1)

Documents

H1200000

Hydrochlorothiazide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-Chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H8ClN3O4S2
CAS Number:
58-93-5
Molecular Weight:
297.74
MDL number:
MFCD00051765
UNSPSC Code:
41116107
PubChem Substance ID:
329815156
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

hydrochlorothiazide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl

InChI

1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)

InChI key

JZUFKLXOESDKRF-UHFFFAOYSA-N

Gene Information

human ... SLC12A3(6559)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Hydrochlorothiazide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Carbonic anhydrase inhibitor

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H351

Hazard Classifications

Carc. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 5

1 of 5

Bisoprolol fumarate European Pharmacopoeia (EP) Reference Standard

Y0000812

Bisoprolol fumarate

Chlorothiazide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1179

Chlorothiazide

Amlodipine besylate United States Pharmacopeia (USP) Reference Standard

USP

1029501

Amlodipine besylate

Valsartan Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1315

Valsartan

Diclofenac sodium salt analytical standard

Supelco

93484

Diclofenac sodium salt

Soham Rej et al.
Drugs & aging, 31(12), 911-916 (2014-10-22)
Little is known about how lithium should be dosed to achieve therapeutic but safe serum concentrations in older adults. In this paper, we investigate how the lithium dose-concentration ratio changes across the lifespan. This was a cross-sectional analysis of 63
Dragos Vinereanu et al.
American heart journal, 168(4), 446-456 (2014-09-30)
The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes. This is a prospective, randomized
Sverre E Kjeldsen et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(6), 380-388 (2013-06-05)
Older patients frequently receive angiotensin II receptor blocker/diuretic combinations to control blood pressure (BP), although there have been relatively few trials specifically examining this patient population. A pooled analysis was performed of data from 7 randomized trials of telmisartan/hydrochlorothiazide combinations
Edgar V Lerma
Current hypertension reports, 13(5), 386-395 (2011-07-29)
Hypertension remains an important problem that increases the risk of cardiovascular disease and is a leading cause of mortality worldwide. Achieving long-term control of arterial hypertension, which has an estimated prevalence of 28% in the US adult population, would translate
James J DiNicolantonio
Expert opinion on pharmacotherapy, 13(6), 807-814 (2012-03-20)
Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service